The global market for Human cytomegalovirus 65 kDa Phosphoprotein was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

North American market for Human cytomegalovirus 65 kDa Phosphoprotein is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Human cytomegalovirus 65 kDa Phosphoprotein is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Human cytomegalovirus 65 kDa Phosphoprotein include Astellas Pharma Inc, Hookipa Biotech AG, Immunomic Therapeutics Inc, Vakzine Projekt Management GmbH, Vaximm AG, VBI Vaccines Inc, Vical Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Human cytomegalovirus 65 kDa Phosphoprotein, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human cytomegalovirus 65 kDa Phosphoprotein.

The Human cytomegalovirus 65 kDa Phosphoprotein market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Human cytomegalovirus 65 kDa Phosphoprotein market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Human cytomegalovirus 65 kDa Phosphoprotein manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Human cytomegalovirus 65 kDa Phosphoprotein Market Report

Report Metric	Details
Report Name	Human cytomegalovirus 65 kDa Phosphoprotein Market
Segment by Type	HB-101 CyMVectin ASP-0113 PepVax Others
Segment by Application	Brain Tumor Hemotaological Tumor Kidney Transplant Rejection Liver Transplant Rejection Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Astellas Pharma Inc, Hookipa Biotech AG, Immunomic Therapeutics Inc, Vakzine Projekt Management GmbH, Vaximm AG, VBI Vaccines Inc, Vical Inc
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human cytomegalovirus 65 kDa Phosphoprotein manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human cytomegalovirus 65 kDa Phosphoprotein in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Human cytomegalovirus 65 kDa Phosphoprotein Market report?

Ans: The main players in the Human cytomegalovirus 65 kDa Phosphoprotein Market are Astellas Pharma Inc, Hookipa Biotech AG, Immunomic Therapeutics Inc, Vakzine Projekt Management GmbH, Vaximm AG, VBI Vaccines Inc, Vical Inc

What are the Application segmentation covered in the Human cytomegalovirus 65 kDa Phosphoprotein Market report?

Ans: The Applications covered in the Human cytomegalovirus 65 kDa Phosphoprotein Market report are Brain Tumor, Hemotaological Tumor, Kidney Transplant Rejection, Liver Transplant Rejection, Others

What are the Type segmentation covered in the Human cytomegalovirus 65 kDa Phosphoprotein Market report?

Ans: The Types covered in the Human cytomegalovirus 65 kDa Phosphoprotein Market report are HB-101, CyMVectin, ASP-0113, PepVax, Others

1 Human cytomegalovirus 65 kDa Phosphoprotein Market Overview

1.1 Product Definition

1.2 Human cytomegalovirus 65 kDa Phosphoprotein by Type

1.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Value Comparison by Type (2024 VS 2031)

1.2.2 HB-101

1.2.3 CyMVectin

1.2.4 ASP-0113

1.2.5 PepVax

1.2.6 Others

1.3 Human cytomegalovirus 65 kDa Phosphoprotein by Application

1.3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Value by Application (2024 VS 2031)

1.3.2 Brain Tumor

1.3.3 Hemotaological Tumor

1.3.4 Kidney Transplant Rejection

1.3.5 Liver Transplant Rejection

1.3.6 Others

1.4 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size Estimates and Forecasts

1.4.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue 2020-2031

1.4.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales 2020-2031

1.4.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Human cytomegalovirus 65 kDa Phosphoprotein Market Competition by Manufacturers

2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Manufacturers (2020-2025)

2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Human cytomegalovirus 65 kDa Phosphoprotein, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Human cytomegalovirus 65 kDa Phosphoprotein, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Human cytomegalovirus 65 kDa Phosphoprotein, Product Type & Application

2.7 Global Key Manufacturers of Human cytomegalovirus 65 kDa Phosphoprotein, Date of Enter into This Industry

2.8 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Competitive Situation and Trends

2.8.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Human cytomegalovirus 65 kDa Phosphoprotein Players Market Share by Revenue

2.8.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Scenario by Region

3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region: 2020-2031

3.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region: 2020-2025

3.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region: 2026-2031

3.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region: 2020-2031

3.3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region: 2020-2025

3.3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region: 2026-2031

3.4 North America Human cytomegalovirus 65 kDa Phosphoprotein Market Facts & Figures by Country

3.4.1 North America Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2020-2031)

3.4.3 North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Facts & Figures by Country

3.5.1 Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2020-2031)

3.5.3 Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Facts & Figures by Region

3.6.1 Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2020-2031)

3.6.3 Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Human cytomegalovirus 65 kDa Phosphoprotein Market Facts & Figures by Country

3.7.1 Latin America Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2020-2031)

3.7.3 Latin America Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Facts & Figures by Country

3.8.1 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2020-2031)

3.8.3 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2020-2031)

4.1.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2020-2025)

4.1.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2026-2031)

4.1.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Type (2020-2031)

4.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2020-2031)

4.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2020-2025)

4.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Type (2026-2031)

4.2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Type (2020-2031)

4.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Price by Type (2020-2031)

5 Segment by Application

5.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2020-2031)

5.1.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2020-2025)

5.1.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2026-2031)

5.1.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Application (2020-2031)

5.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2020-2031)

5.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2020-2025)

5.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Application (2026-2031)

5.2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Application (2020-2031)

5.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Astellas Pharma Inc

6.1.1 Astellas Pharma Inc Company Information

6.1.2 Astellas Pharma Inc Description and Business Overview

6.1.3 Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio

6.1.5 Astellas Pharma Inc Recent Developments/Updates

6.2 Hookipa Biotech AG

6.2.1 Hookipa Biotech AG Company Information

6.2.2 Hookipa Biotech AG Description and Business Overview

6.2.3 Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio

6.2.5 Hookipa Biotech AG Recent Developments/Updates

6.3 Immunomic Therapeutics Inc

6.3.1 Immunomic Therapeutics Inc Company Information

6.3.2 Immunomic Therapeutics Inc Description and Business Overview

6.3.3 Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio

6.3.5 Immunomic Therapeutics Inc Recent Developments/Updates

6.4 Vakzine Projekt Management GmbH

6.4.1 Vakzine Projekt Management GmbH Company Information

6.4.2 Vakzine Projekt Management GmbH Description and Business Overview

6.4.3 Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio

6.4.5 Vakzine Projekt Management GmbH Recent Developments/Updates

6.5 Vaximm AG

6.5.1 Vaximm AG Company Information

6.5.2 Vaximm AG Description and Business Overview

6.5.3 Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio

6.5.5 Vaximm AG Recent Developments/Updates

6.6 VBI Vaccines Inc

6.6.1 VBI Vaccines Inc Company Information

6.6.2 VBI Vaccines Inc Description and Business Overview

6.6.3 VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2020-2025)

6.6.4 VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio

6.6.5 VBI Vaccines Inc Recent Developments/Updates

6.7 Vical Inc

6.7.1 Vical Inc Company Information

6.7.2 Vical Inc Description and Business Overview

6.7.3 Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio

6.7.5 Vical Inc Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Human cytomegalovirus 65 kDa Phosphoprotein Industry Chain Analysis

7.2 Human cytomegalovirus 65 kDa Phosphoprotein Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Human cytomegalovirus 65 kDa Phosphoprotein Production Mode & Process Analysis

7.4 Human cytomegalovirus 65 kDa Phosphoprotein Sales and Marketing

7.4.1 Human cytomegalovirus 65 kDa Phosphoprotein Sales Channels

7.4.2 Human cytomegalovirus 65 kDa Phosphoprotein Distributors

7.5 Human cytomegalovirus 65 kDa Phosphoprotein Customer Analysis

8 Human cytomegalovirus 65 kDa Phosphoprotein Market Dynamics

8.1 Human cytomegalovirus 65 kDa Phosphoprotein Industry Trends

8.2 Human cytomegalovirus 65 kDa Phosphoprotein Market Drivers

8.3 Human cytomegalovirus 65 kDa Phosphoprotein Market Challenges

8.4 Human cytomegalovirus 65 kDa Phosphoprotein Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Astellas Pharma Inc

Hookipa Biotech AG

Immunomic Therapeutics Inc

Vakzine Projekt Management GmbH

Vaximm AG

VBI Vaccines Inc

Vical Inc

List of Tables

Table 1. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Competitive Situation by Manufacturers in 2024

Table 4. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Pcs) of Key Manufacturers (2020-2025)

Table 5. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Human cytomegalovirus 65 kDa Phosphoprotein Average Price (USD/Pcs) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Human cytomegalovirus 65 kDa Phosphoprotein, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Human cytomegalovirus 65 kDa Phosphoprotein, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Human cytomegalovirus 65 kDa Phosphoprotein, Product Type & Application

Table 12. Global Key Manufacturers of Human cytomegalovirus 65 kDa Phosphoprotein, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Human cytomegalovirus 65 kDa Phosphoprotein by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human cytomegalovirus 65 kDa Phosphoprotein as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2020-2025) & (K Pcs)

Table 18. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Region (2020-2025)

Table 19. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2026-2031) & (K Pcs)

Table 20. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Region (2026-2031)

Table 21. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Region (2020-2025)

Table 23. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Region (2026-2031)

Table 25. North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2020-2025) & (K Pcs)

Table 27. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2026-2031) & (K Pcs)

Table 28. North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2020-2025) & (K Pcs)

Table 32. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2026-2031) & (K Pcs)

Table 33. Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2020-2025) & (K Pcs)

Table 37. Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2026-2031) & (K Pcs)

Table 38. Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2020-2025) & (K Pcs)

Table 42. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2026-2031) & (K Pcs)

Table 43. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2020-2025) & (K Pcs)

Table 47. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2026-2031) & (K Pcs)

Table 48. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Pcs) by Type (2020-2025)

Table 51. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Pcs) by Type (2026-2031)

Table 52. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Type (2020-2025)

Table 53. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Type (2026-2031)

Table 54. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Type (2020-2025)

Table 57. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Type (2026-2031)

Table 58. Global Human cytomegalovirus 65 kDa Phosphoprotein Price (USD/Pcs) by Type (2020-2025)

Table 59. Global Human cytomegalovirus 65 kDa Phosphoprotein Price (USD/Pcs) by Type (2026-2031)

Table 60. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Pcs) by Application (2020-2025)

Table 61. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Pcs) by Application (2026-2031)

Table 62. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Application (2020-2025)

Table 63. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Application (2026-2031)

Table 64. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Application (2020-2025)

Table 67. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Application (2026-2031)

Table 68. Global Human cytomegalovirus 65 kDa Phosphoprotein Price (USD/Pcs) by Application (2020-2025)

Table 69. Global Human cytomegalovirus 65 kDa Phosphoprotein Price (USD/Pcs) by Application (2026-2031)

Table 70. Astellas Pharma Inc Company Information

Table 71. Astellas Pharma Inc Description and Business Overview

Table 72. Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 73. Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Product

Table 74. Astellas Pharma Inc Recent Developments/Updates

Table 75. Hookipa Biotech AG Company Information

Table 76. Hookipa Biotech AG Description and Business Overview

Table 77. Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 78. Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Product

Table 79. Hookipa Biotech AG Recent Developments/Updates

Table 80. Immunomic Therapeutics Inc Company Information

Table 81. Immunomic Therapeutics Inc Description and Business Overview

Table 82. Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 83. Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Product

Table 84. Immunomic Therapeutics Inc Recent Developments/Updates

Table 85. Vakzine Projekt Management GmbH Company Information

Table 86. Vakzine Projekt Management GmbH Description and Business Overview

Table 87. Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 88. Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Product

Table 89. Vakzine Projekt Management GmbH Recent Developments/Updates

Table 90. Vaximm AG Company Information

Table 91. Vaximm AG Description and Business Overview

Table 92. Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 93. Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Product

Table 94. Vaximm AG Recent Developments/Updates

Table 95. VBI Vaccines Inc Company Information

Table 96. VBI Vaccines Inc Description and Business Overview

Table 97. VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 98. VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Product

Table 99. VBI Vaccines Inc Recent Developments/Updates

Table 100. Vical Inc Company Information

Table 101. Vical Inc Description and Business Overview

Table 102. Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 103. Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Product

Table 104. Vical Inc Recent Developments/Updates

Table 105. Key Raw Materials Lists

Table 106. Raw Materials Key Suppliers Lists

Table 107. Human cytomegalovirus 65 kDa Phosphoprotein Distributors List

Table 108. Human cytomegalovirus 65 kDa Phosphoprotein Customers List

Table 109. Human cytomegalovirus 65 kDa Phosphoprotein Market Trends

Table 110. Human cytomegalovirus 65 kDa Phosphoprotein Market Drivers

Table 111. Human cytomegalovirus 65 kDa Phosphoprotein Market Challenges

Table 112. Human cytomegalovirus 65 kDa Phosphoprotein Market Restraints

Table 113. Research Programs/Design for This Report

Table 114. Key Data Information from Secondary Sources

Table 115. Key Data Information from Primary Sources

Table 116. Authors List of This Report

List of Figures

Figure 1. Product Picture of Human cytomegalovirus 65 kDa Phosphoprotein

Figure 2. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Share by Type: 2024 & 2031

Figure 4. HB-101 Product Picture

Figure 5. CyMVectin Product Picture

Figure 6. ASP-0113 Product Picture

Figure 7. PepVax Product Picture

Figure 8. Others Product Picture

Figure 9. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Value by Application (2020-2031) & (US$ Million)

Figure 10. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Share by Application: 2024 & 2031

Figure 11. Brain Tumor

Figure 12. Hemotaological Tumor

Figure 13. Kidney Transplant Rejection

Figure 14. Liver Transplant Rejection

Figure 15. Others

Figure 16. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size (2020-2031) & (US$ Million)

Figure 18. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales (2020-2031) & (K Pcs)

Figure 19. Global Human cytomegalovirus 65 kDa Phosphoprotein Average Price (USD/Pcs) & (2020-2031)

Figure 20. Human cytomegalovirus 65 kDa Phosphoprotein Report Years Considered

Figure 21. Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Manufacturers in 2024

Figure 22. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Share by Manufacturers in 2024

Figure 23. Global 5 and 10 Largest Human cytomegalovirus 65 kDa Phosphoprotein Players: Market Share by Revenue in Human cytomegalovirus 65 kDa Phosphoprotein in 2024

Figure 24. Human cytomegalovirus 65 kDa Phosphoprotein Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 25. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 26. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Country (2020-2031)

Figure 27. North America Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Country (2020-2031)

Figure 28. U.S. Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Canada Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Country (2020-2031)

Figure 31. Europe Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Country (2020-2031)

Figure 32. Germany Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. France Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. U.K. Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Italy Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Russia Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Region (2020-2031)

Figure 38. Asia Pacific Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Region (2020-2031)

Figure 39. China Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Japan Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. South Korea Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. India Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Australia Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Taiwan Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Indonesia Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Thailand Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Malaysia Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Philippines Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Country (2020-2031)

Figure 50. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Country (2020-2031)

Figure 51. Mexico Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Brazil Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Argentina Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Country (2020-2031)

Figure 55. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Country (2020-2031)

Figure 56. Turkey Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 57. Saudi Arabia Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 58. UAE Human cytomegalovirus 65 kDa Phosphoprotein Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 59. Global Sales Market Share of Human cytomegalovirus 65 kDa Phosphoprotein by Type (2020-2031)

Figure 60. Global Revenue Market Share of Human cytomegalovirus 65 kDa Phosphoprotein by Type (2020-2031)

Figure 61. Global Human cytomegalovirus 65 kDa Phosphoprotein Price (USD/Pcs) by Type (2020-2031)

Figure 62. Global Sales Market Share of Human cytomegalovirus 65 kDa Phosphoprotein by Application (2020-2031)

Figure 63. Global Revenue Market Share of Human cytomegalovirus 65 kDa Phosphoprotein by Application (2020-2031)

Figure 64. Global Human cytomegalovirus 65 kDa Phosphoprotein Price (USD/Pcs) by Application (2020-2031)

Figure 65. Human cytomegalovirus 65 kDa Phosphoprotein Value Chain

Figure 66. Channels of Distribution (Direct Vs Distribution)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-25N19924

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Needle Free Allergy Therapy Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-24B19783

Fri Nov 28 00:00:00 UTC 2025

Add to Cart

Global Hydrotalcite Antacid Chewable Tablets Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-10T20305

Fri Nov 28 00:00:00 UTC 2025

Add to Cart

Global Dual Orexin Receptor Antagonist Sleeping Pills Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-12S20176

Mon Nov 24 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Human cytomegalovirus 65 kDa Phosphoprotein Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-28D7034

Global Human cytomegalovirus 65 kDa Phosphoprotein Market Research Report 2025

FEATURED COMPANIES

Human cytomegalovirus 65 kDa Phosphoprotein Market

Report Scope

Scope of Human cytomegalovirus 65 kDa Phosphoprotein Market Report

Core Chapters

FAQ for this report

Who are the main players in the Human cytomegalovirus 65 kDa Phosphoprotein Market report?

What are the Application segmentation covered in the Human cytomegalovirus 65 kDa Phosphoprotein Market report?

What are the Type segmentation covered in the Human cytomegalovirus 65 kDa Phosphoprotein Market report?

FEATURED COMPANIES

RELATED REPORTS